NRx Pharmaceuticals Wins Positive FDA Discipline Review for Ketamine ANDA, Seeks Summer 2026 Approval
NRx Pharmaceuticals received a positive Discipline Review Letter from the FDA Office of Generic Drugs requesting only minor administrative changes and updates to prior stability data for its preservative-free ketamine ANDA. FDA leadership voiced support for addressing remaining application aspects within the current review cycle, targeting approval in Summer 2026.
1. Positive FDA Discipline Review Letter
NRx Pharmaceuticals received a Discipline Review Letter from the FDA Office of Generic Drugs covering drug substance, product, manufacturing, and microbiology, with only minor administrative changes and prior stability data updates required. This letter follows the favorable bioequivalence determination issued on March 17, 2026.
2. Support from FDA Leadership
In a meeting with FDA Office of Generic Drugs leadership, NRx secured verbal support to address remaining ANDA elements within the current review cycle, aligning with the President’s April 16, 2026 Executive Order prioritizing rapid antidepressant approvals.
3. Summer 2026 Approval Target
FDA leadership indicated that the preservative-free ketamine ANDA could be approved by Summer 2026, addressing documented supply shortages and providing a benzethonium chloride–free formulation for treatment-resistant depression and suicidality.
4. Ongoing NDA Submission
Alongside the ANDA, NRx is preparing a New Drug Application to align ketamine labeling with its use in severe depression and suicidality, leveraging Fast Track and Breakthrough Therapy designations to expedite market entry.